All In Biotech

Drug Trial Radar · NCT03179436

Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

A Phase 1 / 2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

415

Actual

Start

Jul 2, 2017

Primary completion

Apr 8, 2024

Study completion Apr 8, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • QuavonlimabBiological

    Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.

  • PembrolizumabBiological

    Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).

  • Pembrolizumab/QuavonlimabDrug

    Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With ≥1 Dose Limiting Toxicity (DLT)Time frame: Up to 6 weeks
  2. Number of Participants With ≥1 Adverse Event (AE)Time frame: Up to approximately 77 months
  3. Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to approximately 26 months
  4. Efficacy Expansion: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Based on Adjusted Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to approximately 72 months

Locations

53 sites in 16 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0013)

    Gilbert, Arizona

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)

    Hackensack, New Jersey

  • Tennessee Oncology Nashville ( Site 0004)

    Nashville, Tennessee

  • South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)

    San Antonio, Texas

  • Inova Schar Cancer Institute ( Site 1001)

    Fairfax, Virginia

  • Blacktown Hospital. Western Sydney local health district ( Site 0009)

    Blacktown, New South Wales, Australia

  • Calvary Mater Newcastle ( Site 0025)

    Waratah, New South Wales, Australia

  • Melanoma Institute Australia ( Site 0017)

    Wollstonecraft, New South Wales, Australia

  • Gallipoli Medical Research Foundation-GMRF CTU ( Site 0019)

    Brisbane, Queensland, Australia

  • Cairns and Hinterland Hospital and Health Service ( Site 0020)

    Cairns, Queensland, Australia

  • Ashford Cancer Centre Research ( Site 0012)

    Kurralta Park, South Australia, Australia

  • Ballarat Health Services ( Site 0022)

    Ballarat, Victoria, Australia

  • Alfred Health ( Site 0018)

    Melbourne, Victoria, Australia

  • Sunnybrook Research Institute ( Site 1103)

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Centre ( Site 1104)

    Toronto, Ontario, Canada

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1102)

    Montreal, Quebec, Canada

  • Jewish General Hospital ( Site 1105)

    Montreal, Quebec, Canada

  • McGill University Health Centre ( Site 1101)

    Montreal, Quebec, Canada

  • Fundacion Arturo Lopez Perez ( Site 5601)

    Santiago, Region M. de Santiago, Chile

  • Beijing Cancer hospital-Digestive Oncology ( Site 5001)

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital-Phase 1 Unite ( Site 5004)

    Chongqing, Chongqing Municipality, China

  • Sir Run Run Shaw Hospital-Medical Oncology ( Site 5003)

    Hangzhou, Zhejiang, China

  • Hopital La Timone ( Site 3303)

    Marseille, Bouches-du-Rhone, France

  • Institut Bergonie ( Site 3306)

    Bordeaux, Gironde, France

  • CHRU Lille - Hopital Claude Huriez ( Site 3302)

    Lille, Nord, France

  • CH Lyon Sud Hospices Civils de Lyon ( Site 3307)

    Pierre-Bénite, Rhone, France

  • Gustave Roussy ( Site 3305)

    Villejuif, Val-de-Marne, France

  • Regional General Hospital of Athens "Laiko" ( Site 3001)

    Athens, Attica, Greece

  • Rambam Medical Center ( Site 0003)

    Haifa, Israel

  • Hadassah Ein Karem Hebrew University Medical Center ( Site 0021)

    Jerusalem, Israel

  • Sheba Medical Center - Cancer Center ( Site 0002)

    Ramat Gan, Israel

  • Istituto Nazionale Tumori Fondazione Pascale ( Site 3903)

    Naples, Italy

  • IRCCS Istituto Oncologico Veneto ( Site 3905)

    Padova, Italy

  • Policlinico Le Scotte - A.O. Senese ( Site 3907)

    Siena, Italy

  • National Cancer Center Hospital East ( Site 0014)

    Kashiwa, Chiba, Japan

  • Hyogo Cancer Center ( Site 0015)

    Akashi, Hyōgo, Japan

  • Auckland City Hospital ( Site 0016)

    Auckland, New Zealand

  • Canterbury District Health Board ( Site 0023)

    Christchurch, Canterbury, New Zealand

  • Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 4803)

    Poznan, Greater Poland Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4801

    Warsaw, Masovian Voivodeship, Poland

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.